CALML5
Calmodulin-like protein 5
Also known as: CALL5_HUMAN, CLSP
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9NZT1
- Gene
- CALML5
- Ensembl
- ENSG00000178372
- Chromosome
- 10
- Canonical length
- 146 aa
- Protein class
- Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins
- Subcellular location
- Plasma membrane,Cytosol
OverviewNCBI Gene
This gene encodes a novel calcium binding protein expressed in the epidermis and related to the calmodulin family of calcium binding proteins. Functional studies with recombinant protein demonstrate it does bind calcium and undergoes a conformational change when it does so. Abundant expression is detected only in reconstructed epidermis and is restricted to differentiating keratinocytes. In addition, it can associate with transglutaminase 3, shown to be a key enzyme in the terminal differentiation of keratinocytes. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
146 residues, UniProt reviewed canonical sequence.
>Q9NZT1|CALML5
1 MAGELTPEEE AQYKKAFSAV DTDGNGTINA QELGAALKAT GKNLSEAQLR KLISEVDSDG
61 DGEISFQEFL TAAKKARAGL EDLQVAFRAF DQDGDGHITV DELRRAMAGL GQPLPQEELD
121 AMIREADVDQ DGRVNYEEFA RMLAQELocalizationUniProt · AlphaFold · HPA
Whether an antibody against CALML5 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.37
- Highest tissue expression
- 2,987 nTPM
Expression across tissuesHPA
Tissue
- skin: 2,987 nTPM
- salivary gland: 522 nTPM
- vagina: 273 nTPM
- cervix: 199 nTPM
- esophagus: 64 nTPM
- breast: 39 nTPM
Single-cell type
- esophageal apical cells: 921 nCPM
- salivary acinar cells: 610 nCPM
- suprabasal keratinocytes: 333 nCPM
- breast secretory cells: 204 nCPM
- esophageal suprabasal cells: 168 nCPM
- salivary myoepithelial cells: 143 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- amygdala: 0 nTPM
- basal ganglia: 0 nTPM
- cerebellum: 0 nTPM
- cerebral cortex: 0 nTPM
- choroid plexus: 0 nTPM
- hippocampal formation: 0 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD missense Z
- 0.72
- DepMap mean gene effect
- 0.01
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of CALML5 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads CALML5 as an antibody target. Whether an autoantibody or antibody against CALML5 could matter depends on whether native CALML5 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
CALML5 is annotated as secreted, so native CALML5 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label CALML5 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...